A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Trial Profile

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Tivozanib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms TIVO-3
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 09 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to an AVEO Oncology media release.
    • 20 Jun 2017 According to an AVEO Oncology media release, a pre-planned futility analysis of the trial is expected around midyear 2017, with topline data expected in the first quarter of 2018.
    • 20 Jun 2017 According to an AVEO Oncology media release, target enrollment of 322 patients has been reached in the trial, the study will continue enrolling additional patients for the next few weeks to replace early dropouts.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top